These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
56 related items for PubMed ID: 21652029
21. Exenatide and biotin in conjunction with a protein-sparing fast for normalization of beta cell function in type 2 diabetics. McCarty MF. Med Hypotheses; 2007; 69(4):928-32. PubMed ID: 17292559 [Abstract] [Full Text] [Related]
22. Exenatide Treatment Causes Suppression of Serum Ghrelin Levels following Mixed Meal Test in Obese Diabetic Women. Topyildiz F, Kiyici S, Gul Z, Sigirli D, Guclu M, Kisakol G, Cavun S. J Diabetes Res; 2016; 2016():1309502. PubMed ID: 26998491 [Abstract] [Full Text] [Related]
23. Twelve weeks' treatment with diazoxide without insulin supplementation in Type 2 diabetes is feasible but does not improve insulin secretion. Radtke M, Kollind M, Qvigstad E, Grill V. Diabet Med; 2007 Feb; 24(2):172-7. PubMed ID: 17257280 [Abstract] [Full Text] [Related]
24. Effect of exenatide therapy on hepatic fat quantity and hepatic biomarkers in type 2 diabetic patients. Blaslov K, Zibar K, Bulum T, Duvnjak L. Clin Res Hepatol Gastroenterol; 2014 Jun; 38(3):e61-3. PubMed ID: 24315013 [No Abstract] [Full Text] [Related]
26. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Bunck MC, Diamant M, Eliasson B, Cornér A, Shaginian RM, Heine RJ, Taskinen MR, Yki-Järvinen H, Smith U. Diabetes Care; 2010 Aug; 33(8):1734-7. PubMed ID: 20424219 [Abstract] [Full Text] [Related]
27. Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study. Gastaldelli A, Gaggini M, Daniele G, Ciociaro D, Cersosimo E, Tripathy D, Triplitt C, Fox P, Musi N, DeFronzo R, Iozzo P. Hepatology; 2016 Dec; 64(6):2028-2037. PubMed ID: 27639082 [Abstract] [Full Text] [Related]
28. Myths about Insulin Resistance: Tribute to Gerald Reaven. Kim SH, Abbasi F. Endocrinol Metab (Seoul); 2019 Mar; 34(1):47-52. PubMed ID: 30912338 [Abstract] [Full Text] [Related]
35. Formononetin attenuates IL-1β-induced apoptosis and NF-κB activation in INS-1 cells. Wang Y, Zhu Y, Gao L, Yin H, Xie Z, Wang D, Zhu Z, Han X. Molecules; 2012 Aug 24; 17(9):10052-64. PubMed ID: 22922276 [Abstract] [Full Text] [Related]
38. Dysregulation of glucose metabolism in HIV patients: epidemiology, mechanisms, and management. Gutierrez AD, Balasubramanyam A. Endocrine; 2012 Feb 24; 41(1):1-10. PubMed ID: 22134974 [Abstract] [Full Text] [Related]
40. Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection. Sheffield CA, Kane MP, Busch RS. Pharmacotherapy; 2007 Oct 24; 27(10):1449-55. PubMed ID: 17896900 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]